FibroScan / VCTE: Which Tests to Order Alongside

What FibroScan (VCTE) Actually Measures

FibroScan uses a mechanical pulse to generate a shear wave through liver tissue, then measures its velocity. Stiffer tissue transmits waves faster, producing a higher kilopascal (kPa) reading. The device simultaneously captures the controlled attenuation parameter (CAP), an ultrasound-based estimate of hepatic steatosis reported in decibels per meter (dB/m).

A single FibroScan session takes about 10 minutes. It is painless. But the two numbers it produces, liver stiffness measurement (LSM) and CAP, answer only part of the clinical question. LSM can be elevated by inflammation, cholestasis, hepatic congestion, or even a recent meal, not just fibrosis [1]. The AASLD 2023 practice guidance on noninvasive assessment of liver disease explicitly states that "liver stiffness should be interpreted in clinical context, alongside biochemical and clinical data" [1]. This is why paired laboratory testing is not optional. It is the difference between a number and a diagnosis.

Why a FibroScan Alone Is Not Enough

VCTE has strong negative predictive value for excluding advanced fibrosis (≥F3), exceeding 90% in several validation cohorts [2]. Its positive predictive value, however, drops in populations with high rates of obesity, type 2 diabetes, or active hepatic inflammation. A 2021 meta-analysis in Hepatology (N=5,735) found that LSM overestimated fibrosis stage in 18.4% of patients with ALT levels more than twice the upper limit of normal [2].

Ordering paired labs corrects for these confounders. A normal ALT tells the clinician that an elevated kPa reading is less likely to be driven by acute inflammation. An elevated GGT or alkaline phosphatase may point toward cholestatic overlap. A high ferritin could suggest hemochromatosis rather than MASLD. Each lab result sharpens the FibroScan's clinical meaning.

The Core Paired Panel: What Every FibroScan Order Should Include

The following tests form the minimum paired panel for any patient undergoing VCTE for suspected or known MASLD. This is based on recommendations from the AACE 2022 clinical practice guideline for the diagnosis and management of NAFLD and the ADA Standards of Care 2024 [3][4].

FIB-4 Index (Calculated from Age, AST, ALT, Platelet Count)

FIB-4 is a free, validated formula. It requires only four inputs already present in routine blood work: patient age, AST, ALT, and platelet count. The AASLD and AGA both recommend FIB-4 as the initial screening step before VCTE [1][5].

Interpretation thresholds:

• FIB-4 <1.3: low risk of advanced fibrosis (negative predictive value ~90%)
• FIB-4 1.3 to 2.67: indeterminate, proceed to VCTE or ELF test
• FIB-4 >2.67: high probability of advanced fibrosis

When FIB-4 and VCTE agree, diagnostic confidence is high. When they disagree, the clinician has reason to order additional workup or consider biopsy.

Comprehensive Metabolic Panel (CMP)

The CMP provides AST, ALT, albumin, bilirubin, alkaline phosphatase, glucose, and creatinine in a single draw. AST and ALT feed the FIB-4 calculation. Albumin and bilirubin contribute to prognostic scores like MELD. Fasting glucose adds metabolic context, since MASLD and type 2 diabetes co-occur in roughly 55% to 70% of patients with biopsy-confirmed MASH [6].

Complete Blood Count (CBC)

Platelets are required for the FIB-4 formula. A platelet count below 150,000/µL independently suggests portal hypertension or advanced fibrosis. The Baveno VII consensus uses the combination of LSM <20 kPa and platelet count ≥150,000/µL to rule out clinically significant portal hypertension without endoscopy [7].

Hemoglobin A1c

HbA1c identifies insulin resistance and overt diabetes, both of which accelerate fibrosis progression in MASLD. The ADA Standards of Care recommend screening all patients with hepatic steatosis for diabetes, and vice versa [4]. An HbA1c of 5.7% to 6.4% (prediabetes) in a patient with elevated CAP and LSM changes management: it may trigger metformin initiation, GLP-1 receptor agonist consideration, or both.

Fasting Lipid Panel

Dyslipidemia is present in the majority of MASLD patients. A fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) informs cardiovascular risk stratification, which matters because cardiovascular disease, not liver failure, is the leading cause of death in patients with MASLD [8]. A triglyceride level above 150 mg/dL also strengthens the metabolic syndrome diagnosis that underpins MASLD classification.

Extended Panel: When to Go Beyond the Basics

Not every patient needs the tests below. But specific clinical scenarios call for them.

Iron Studies (Ferritin and Transferrin Saturation)

Ferritin above 300 ng/mL in men or 200 ng/mL in women warrants transferrin saturation testing to exclude hereditary hemochromatosis. Elevated ferritin is common in MASLD, affecting roughly 20% to 50% of patients [9]. A transferrin saturation above 45% triggers HFE gene testing per AASLD guidance on hemochromatosis [9]. Without this test, a high LSM on FibroScan could be attributed to MASLD when iron overload is the true driver.

Thyroid-Stimulating Hormone (TSH)

Hypothyroidism independently increases hepatic fat accumulation. A 2022 analysis from the Rotterdam Study (N=9,419) demonstrated that subclinical hypothyroidism (TSH >4.0 mIU/L) was associated with a 1.24-fold increased risk of MASLD (95% CI, 1.01 to 1.53) [10]. Checking TSH is especially relevant in women over 50 and in patients whose steatosis degree seems disproportionate to their metabolic risk profile.

Hepatitis B and C Serologies

Chronic viral hepatitis confounds FibroScan results. Hepatitis C in particular causes both steatosis and fibrosis that mimic MASLD. The USPSTF recommends universal hepatitis C screening for all adults aged 18 to 79 years [11]. If a patient has never been screened, the FibroScan visit is an efficient time to draw HCV antibody and HBsAg.

Autoimmune Markers (ANA, ASMA, IgG)

When ALT is elevated out of proportion to the degree of steatosis, or when the patient is a young woman with no metabolic risk factors, autoimmune hepatitis enters the differential. An antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA), and total IgG level can be drawn at the same visit.

GLP-1 Receptor Agonist and Resmetirom Eligibility Labs

For patients being evaluated for pharmacotherapy, specific labs determine treatment eligibility. Resmetirom (Rezdiffra), the first FDA-approved drug for MASH with moderate to advanced fibrosis (F2-F3), requires documentation of fibrosis stage [12]. The FDA label permits staging by liver biopsy or noninvasive methods, making VCTE plus FIB-4 a viable pathway [12]. A baseline TSH is required before starting resmetirom because it is a thyroid hormone receptor beta agonist. TSH must be normal and should be monitored every 6 to 12 months on therapy.

For GLP-1 receptor agonists being considered for their hepatic benefits, HbA1c and eGFR inform dosing decisions and renal safety monitoring. Semaglutide's phase 2 liver-specific data showed a 43% histological resolution of MASH without worsening fibrosis at 72 weeks in patients receiving 0.4 mg daily (N=320) [13].

How to Interpret FibroScan Results in Context with Labs

Liver stiffness results gain meaning only when read alongside the paired panel. Here is a practical clinical framework.

LSM <7.0 kPa with FIB-4 <1.3 and normal ALT: Low risk. No advanced fibrosis is likely. If CAP is elevated (≥248 dB/m), lifestyle intervention for steatosis is appropriate. Repeat VCTE in 2 to 3 years if metabolic risk factors persist.

LSM 7.0 to 9.9 kPa with FIB-4 1.3 to 2.67: Indeterminate zone. The AASLD guidance recommends considering the Enhanced Liver Fibrosis (ELF) test or MR elastography to resolve the uncertainty [1]. Hepatology referral is reasonable. Check for confounders: Was the patient fasting? Is ALT acutely elevated? Is there heart failure causing hepatic congestion?

LSM ≥10.0 kPa with FIB-4 >2.67 and low platelets: High probability of advanced fibrosis (F3-F4). This concordance between VCTE and serum markers carries a positive predictive value exceeding 80% for ≥F3 in MASLD populations [2]. Hepatology referral is indicated. Consider hepatocellular carcinoma surveillance with ultrasound every 6 months if cirrhosis (F4) is suspected, per AASLD HCC surveillance guidance [14].

LSM elevated but FIB-4 low: This discordance demands investigation. Check for technical causes (BMI >40, ascites, narrow intercostal spaces), inflammatory confounders (ALT flare, acute hepatitis), or non-fibrotic stiffness elevation (cardiac congestion, cholestasis, amyloidosis). A repeat VCTE after 3 months with confirmed fasting (minimum 2 hours, ideally 4 hours) may resolve the discrepancy.

Monitoring Over Time: When to Repeat the FibroScan and Labs

Serial VCTE provides objective fibrosis tracking without repeated biopsies. The European Association for the Study of the Liver (EASL) recommends repeating VCTE every 1 to 2 years in patients with known or suspected MASLD and persistent metabolic risk [15]. A clinically meaningful change in LSM is generally considered to be ≥20% relative change from baseline, as smaller fluctuations fall within the test's inherent variability.

Dr. Rohit Loomba, director of the MASLD Research Center at UC San Diego, has noted: "The combination of serial VCTE with FIB-4 trending gives us a noninvasive monitoring strategy that, for the first time, can track fibrosis regression on therapy without repeated biopsies" [16].

At each repeat FibroScan, the paired lab panel should be redrawn. HbA1c trends reveal whether metabolic control is improving. ALT normalization on therapy is a favorable signal. Platelet count decline over serial measurements may indicate progressive portal hypertension even when LSM remains stable.

Practical Ordering Checklist

For clinicians ordering a FibroScan, here is the minimum and extended lab order set, consolidated for a single blood draw at the same visit.

Minimum panel (all patients):

• CMP (includes AST, ALT, albumin, bilirubin, alkaline phosphatase, glucose, creatinine)
• CBC with differential (includes platelet count for FIB-4)
• HbA1c
• Fasting lipid panel

Extended panel (situation-dependent):

• Ferritin and transferrin saturation (if ferritin previously elevated or unknown)
• TSH (if considering resmetirom, or if steatosis is unexplained)
• HCV antibody and HBsAg (if never screened)
• ANA, ASMA, IgG (if autoimmune hepatitis is in the differential)
• GGT (adds specificity to fibrosis scoring algorithms like the NAFLD Fibrosis Score)
• Fasting insulin (if insulin resistance quantification is desired for research or clinical protocols)

Patients should fast for at least 2 hours before FibroScan (food intake can increase LSM by 1 to 3 kPa) and at least 8 hours if a fasting lipid panel and fasting glucose are included in the blood draw [1].